0000899243-21-039183.txt : 20211005
0000899243-21-039183.hdr.sgml : 20211005
20211005160521
ACCESSION NUMBER: 0000899243-21-039183
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211001
FILED AS OF DATE: 20211005
DATE AS OF CHANGE: 20211005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOHNSON DAVID LEE
CENTRAL INDEX KEY: 0001733883
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 211306647
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS
STREET 2: 171 OYSTER POINT BLVD, STE. 300
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-10-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001733883
JOHNSON DAVID LEE
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO,
CA
94080
0
1
0
0
Chief Commercial Officer
Common Stock
2021-10-01
4
M
0
4375
A
41242
D
Common Stock
2021-10-01
4
F
0
2170
26.25
D
39072
D
Restricted Stock Units
2021-10-01
4
M
0
4375
0.00
D
Common Stock
4375
4375
D
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 4,375 shares of Common Stock underlying the Reporting Person's RSUs.
The shares of Common Stock underlying the RSUs vested with respect to 1/4th of the underlying shares on April 1, 2019. Thereafter, 1/6th of the remaining underlying shares vest on a semi-annual basis until fully vested on April 1, 2022, subject to the Reporting Person's continuous service with the Issuer. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
/s/ Miguel Carrillo, as Attorney-in-Fact
2021-10-05